Payment overview · 2025
General Payments
$998.54
52 reported records · 17 companies
Healthcare provider profile · identity verified
Mark Schaaf, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · MOUNT MORRIS, MI · NPI 1306932611
Verified facts
What the public records show
CMS Open Payments records show Mark Schaaf, D.O. received $998.54 in general payments during 2025 across 52 reported records.
AstraZeneca Pharmaceuticals LP accounted for 26.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Paxlovid, Rybelsus, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 168 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 168 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $267.33 | 26.8% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $147.07 | 14.7% | 14 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $82.40 | 8.2% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $82.16 | 8.2% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $62.31 | 6.2% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $57.81 | 5.8% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $46.03 | 4.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $35.55 | 3.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $33.91 | 3.4% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $29.00 | 2.9% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $27.05 | 2.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $24.17 | 2.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.01 | 2.4% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $23.16 | 2.3% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $20.62 | 2.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $19.69 | 2.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.27 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $998.54 | 52 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $124.42 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $112.74 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $82.40 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $82.16 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $82.10 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $75.68 | 10 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $71.39 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $63.85 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $62.31 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $62.31 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $57.81 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $46.03 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $43.43 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $35.55 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $29.00 | 1 | 2025 |
Source payment records
|
|||||
| COSENTYX Normalized: cosentyx |
Drug | Novartis Pharmaceuticals Corporation | $27.05 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $24.17 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $23.16 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $20.62 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $19.69 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $16.27 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.49 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 52 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 120 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 30 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 114 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
52 | 13 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
120 | 30 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
168 | 41 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
114 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
120 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
168 | 41 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
30 | 30 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1592 | 218 |
| Levothyroxine Sodium | Levothyroxine Sodium | 574 | 146 |
| Atorvastatin Calcium | Atorvastatin Calcium | 564 | 155 |
| Amlodipine Besylate | Amlodipine Besylate | 559 | 152 |
| Lisinopril | Lisinopril | 478 | 134 |
| Omeprazole | Omeprazole | 444 | 124 |
| Alprazolam | Alprazolam | 407 | 73 |
| Gabapentin | Gabapentin | 369 | 112 |
| Simvastatin | Simvastatin | 362 | 105 |
| Metoprolol Succinate | Metoprolol Succinate | 360 | 102 |
| Tamsulosin Hcl | Tamsulosin Hcl | 339 | 99 |
| Metoprolol Tartrate | Metoprolol Tartrate | 337 | 97 |
| Prednisone | Prednisone | 326 | 175 |
| Losartan Potassium | Losartan Potassium | 300 | 87 |
| Potassium Chloride | Potassium Chloride | 285 | 84 |
| Metformin Hcl | Metformin Hcl | 270 | 75 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 250 | 87 |
| Famotidine | Famotidine | 245 | 75 |
| Meloxicam | Meloxicam | 239 | 82 |
| Furosemide | Furosemide | 236 | 79 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 234 | 91 |
| Allopurinol | Allopurinol | 233 | 66 |
| Sertraline Hcl | Sertraline Hcl | 202 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 200 | 57 |
| Ibuprofen | Ibuprofen | 179 | 58 |
| Tramadol Hcl | Tramadol Hcl | 175 | 33 |
| Carvedilol | Carvedilol | 174 | 47 |
| Eliquis | Apixaban | 168 | 41 |
| Cephalexin | Cephalexin | 159 | 127 |
| Pravastatin Sodium | Pravastatin Sodium | 155 | 40 |
| Azithromycin | Azithromycin | 151 | 95 |
| Metformin Hcl Er | Metformin Hcl | 151 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 149 | 42 |
| Glimepiride | Glimepiride | 145 | 43 |
| Diazepam | Diazepam | 142 | 28 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 140 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 138 | 66 |
| Hydrochlorothiazide | Hydrochlorothiazide | 135 | 40 |
| Montelukast Sodium | Montelukast Sodium | 135 | 45 |
| Clonazepam | Clonazepam | 132 | 20 |
| Jardiance | Empagliflozin | 120 | 30 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 114 | 30 |
| Amoxicillin | Amoxicillin | 113 | 72 |
| Glipizide Er | Glipizide | 106 | 32 |
| Hydralazine Hcl | Hydralazine Hcl | 101 | 29 |
| Dicyclomine Hcl | Dicyclomine Hcl | 97 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 96 | 74 |
| Oxycodone Hcl | Oxycodone Hcl | 96 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 93 | 63 |
| Trazodone Hcl | Trazodone Hcl | 92 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 89 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 89 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 84 | 28 |
| Finasteride | Finasteride | 84 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 82 | 23 |
| Donepezil Hcl | Donepezil Hcl | 81 | 26 |
| Temazepam | Temazepam | 81 | 19 |
| Lorazepam | Lorazepam | 80 | 23 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 79 | 20 |
| Fluconazole | Fluconazole | 78 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 74 | 30 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 74 | 24 |
| Buspirone Hcl | Buspirone Hcl | 72 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 72 | 22 |
| Ezetimibe | Ezetimibe | 71 | 22 |
| Bumetanide | Bumetanide | 67 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 66 | 26 |
| Naproxen | Naproxen | 63 | 24 |
| Meclizine Hcl | Meclizine Hcl | 62 | 28 |
| Ramipril | Ramipril | 62 | 16 |
| Spironolactone | Spironolactone | 61 | 20 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 58 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 58 | 15 |
| Enalapril Maleate | Enalapril Maleate | 58 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 57 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 57 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 57 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 57 | 27 |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 55 | 26 |
| Alendronate Sodium | Alendronate Sodium | 54 | 17 |
| Celecoxib | Celecoxib | 53 | 16 |
| Farxiga | Dapagliflozin Propanediol | 52 | 13 |
| Hydromorphone Hcl | Hydromorphone Hcl | 52 | suppressed |
| Lubiprostone | Lubiprostone | 52 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 52 | 17 |
| Nifedipine Er | Nifedipine | 51 | 19 |
| Pregabalin | Pregabalin | 51 | 19 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 50 | suppressed |
| Atenolol | Atenolol | 50 | 16 |
| Levofloxacin | Levofloxacin | 47 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 45 | 11 |
| Fentanyl | Fentanyl | 45 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 45 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 44 | suppressed |
| Januvia | Sitagliptin Phosphate | 43 | 12 |
| Mounjaro | Tirzepatide | 43 | suppressed |
| Mupirocin | Mupirocin | 43 | 33 |
| Mirtazapine | Mirtazapine | 42 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 41 | 21 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 40 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 38 | suppressed |
| Xarelto | Rivaroxaban | 37 | 12 |
| Azelastine Hcl | Azelastine Hcl | 36 | 18 |
| Ozempic | Semaglutide | 36 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 35 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 34 | 12 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 34 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 34 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | 13 |
| Memantine Hcl | Memantine Hcl | 34 | suppressed |
| Nitroglycerin | Nitroglycerin | 34 | 20 |
| Nystatin | Nystatin | 33 | 17 |
| Ranolazine Er | Ranolazine | 33 | suppressed |
| Repatha Sureclick | Evolocumab | 33 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 31 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Methylprednisolone | Methylprednisolone | 31 | 23 |
| Risperidone | Risperidone | 31 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 31 | suppressed |
| Chlorthalidone | Chlorthalidone | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 30 | 30 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 23 |
| Topiramate | Topiramate | 30 | 11 |
| Lamotrigine | Lamotrigine | 29 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 21 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 28 | suppressed |
| Methocarbamol | Methocarbamol | 28 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 28 | 13 |
| Cefuroxime | Cefuroxime Axetil | 27 | 22 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 27 | 20 |
| Spiriva Respimat | Tiotropium Bromide | 27 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 26 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 25 | suppressed |
| Invokana | Canagliflozin | 24 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 24 | 18 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Rybelsus | Semaglutide | 23 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Methadone Hcl | Methadone Hcl | 22 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 22 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 22 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Baclofen | Baclofen | 21 | 13 |
| Fenofibrate | Fenofibrate,micronized | 21 | suppressed |
| Methotrexate | Methotrexate Sodium | 21 | suppressed |
| Metolazone | Metolazone | 21 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 20 | 12 |
| Clotrimazole | Clotrimazole | 20 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | 15 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 19 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 18 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 17 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Testosterone | Testosterone | 17 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Premarin | Estrogens, Conjugated | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Zaleplon | Zaleplon | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Felodipine Er | Felodipine | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Leflunomide | Leflunomide | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Xifaxan | Rifaximin | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Ibu | Ibuprofen | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Oxaprozin | Oxaprozin | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $998.54 · 52 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, COBENFY, COSENTYX, EVENITY, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, Korlym, MOUNJARO, Ozempic, PAXLOVID, QULIPTA, REXULTI, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, YUPELRI, ZEPBOUND, ZORYVE | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error